Neurology® Podcast

Show description/summary:1) Evaluating the safety of beta-interferons in multiple sclerosis 2) Neurology® Today: New Classifications of Seizures and Epilepsies Include New Seizure Types, Simpler TermsThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the June 13, 2017 issue of Neurology. In the first segment, Dr. Michael Levy talks with Dr. Helen Tremlett and Dr. Hilda De Jong about their paper on evaluating the safety of beta-interferons in multiple sclerosis. In the next part of the podcast Dr. Nathan Fountain focuses his interview with Dr. Robert Fisher on the new classifications of seizures and epilepsies presented by the International League Against Epilepsy. Disclosures can be found at Neurology.org.DISCLOSURES:Dr. Levy serves on advisory boards for Asterias, Chugai, and Alexion; serves as Editorial Board member of Multiple Sclerosis and Related Disorders; holds patents for an aquaporin-4 sequence that elicits pathogenic T cell response in animal model of neuromyelitis optica, and for use of a peptide for diagnostic and therapeutic developments; has consulted for Guidepoint Global, Gerson Lehrman Group, and Cowen Group; and has received research support from Viropharma/Shire, Acorda, ApoPharma and Sanofi, Genzyme, Alnylam, Alexion, Terumo BCT, National Institute of Neurological Diseases and Stroke, and Guthy-Jackson Charitable Foundation.Dr. Tremlett has served on scientific advisory boards for US National MS Society and the Centers for Disease Control and Prevention; is the Canada Research Chair for Neuroepidemiology and Multiple Sclerosis; has received research support from the National Multiple Sclerosis Society, the Canadian Institutes of Health Research, Canada Foundation for Innovation, the Multiple Sclerosis Society of Canada, US National Multiple Sclerosis Society, Multiple Sclerosis Scientific Research Foundation, Michael Smith Foundation for Health Research, and the UK MS Trust; has received speaker honoraria and/or travel expenses to attend conferences from the Consortium of MS Centres, the National MS Society, ECTRIMS, the Chesapeake Health Education Program, US Veterans Affairs, Novartis Canada, Biogen Idec, American Academy of Neurology.Dr. Fountain is an epileptologist at the University of Virginia Comprehensive Epilepsy Program (100% effort).All other participants report no disclosures.

Interviews on evaluation of the anoxic brain injury patient.

1) Neurology® Neuroimmunology & Neuroinflammation: Therapy with natalizumab is associated with high JCV sero-conversion and rising JCV index values 2) What's Trending: Interviews with Sandi Moriarity and Andy Lucas about their positions and responsibilities with the Neurology podcasts3) Topic of the month: Pediatric multiple sclerosis This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Melanie Ward interviews Dr. Nicholas Schwab about his Neurology: Neuroimmunology & Neuroinflammation paper on therapy with natalizumab and how it is associated with high JCV sero-conversion and rising JCV index values. Dr. Ted Burns is interviewing Sandi Moriarity and Andy Lucas for our “What's Trending” feature of the week about their positions and responsibilities with the Neurology podcast. In the next part of the podcast Dr. Ruth Ann Marrie interviews Dr. Brenda Banwell about the topic of diagnosis of pediatric multiple sclerosis and acute disseminated encephalomyelitis.DISCLOSURES: Dr. Schwab received funding for travel expenses from Biogen Idec; received speaking honoraria from Novartis; has a patent for Usage of L-selectin as predictive marker for progressive multifocal leukoencephalopathy; and receives research support from the Deutsche Forschungsgemeinschaft German Research Foundation and University Münster, IMF.Dr. Ted Burns serves as Podcast Editor for Neurology; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Sandi Moriarity is Senior Production Editor, Neurology.Andy Lucas is Audio-Visual Administrator, American Academy of Neurology.Dr. Marrie serves as an editorial board member of Neurology and Multiple Sclerosis Journal; receives research support for clinical trials from Sanofi-Aventis, from the Canadian Institutes of Health Research, Research Manitoba, from Multiple Sclerosis Society of Canada and the National Multiple Sclerosis Society, from Multiple Sclerosis Scientific Foundation and from Consortium of Multiple Sclerosis Centers; received research support from the Public Health Agency of Canada.Dr. Banwell serves as an editorial board member of Neurology and Multiple Sclerosis and Related Disorders; serves on the scientific advisory board for Biogen Idec, Sanofi-aventis, Eli Lilly and Company, Novartis; served as a consultant to Biogen Idec, Eli Lilly and Company, Sanofi-aventis; spoken at an event supported by the Consortium of MS Centers; receives research support from the Multiple Sclerosis Society of Canada, Multiple Sclerosis Scientific Research Foundation, and the National Multiple Sclerosis Society.NO CME WILL BE OFFERED THIS WEEK.

1) Why brain death is considered death and 2) Topic of the month: Neuro-infectious diseases. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mike Brogan interviews Drs. Chris Burkle and Eelco Wijdicks about their paper on why brain death is considered death. Dr. Adam Numis is reading our e-Pearl of the week about equine encephalitides. In the next part of the podcast Dr. Chenjie Xia interviews Dr. David Clifford about progressive multifocal leukoencephalopathy and neurologic care of patients with HIV/AIDS. The participants had nothing to disclose except Drs. Wijdicks, Numis and Clifford.Dr. Wijdicks served as Editor-in-Chief of Neurocritical Care and receives royalties from the publication of several books published by Oxford University Press.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Clifford has served/serves on scientific advisory boards for Amgen, Biogen Idec/Quintiles, BMS, Genentech, Inc., Genzyme Corporation, Pfizer Inc, Millennium Pharmaceuticals, Inc. and Sanofi-aventis; received a speaker honorarium from Sun Pharmaceuticals; serves/has served as a consultant for Millennium Pharmaceuticals, Inc., Genzyme Corporation, Biogen Idec, IAS-USA, CMSC/ACTRIMS, ECTRIMS, Drinker, Biddle, Reath, Cytheris and Novartis; receives research support from Lilly, Roche, Alzheimer Association and the NIH (NIMH, NINR); and has provided consultation in medico-legal cases.

Dr. Kait Nevel talks with Dr. Oumaima Aboubakr about the prevalence of epilepsy in primary CNS lymphoma, to identify factors associated with epilepsy, and to investigate the prognostic significance of seizures in PCNSL.

Read the related article in Neurology®.

Disclosures can be found at Neurology.org.